NeuroMetrix Inc. has received a $2m advance from GlaxoSmithKline PLC in a modification of the firms' agreement for GSK to provide up to $13.8m funding for development and commercialization of NeuroMetrix' Quell wearable pain-relief technology.
The modifications announced Dec. 11 accelerated a portion of milestones remaining in the firms' agreement over the next 12 months and reduced GSK's aggregate amount payable by an interest charge
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?